VitriVax is a formulation technology company that engineers solutions to maximize the accessibility and utility of human vaccines.
VitriVax has raised $17.3M in total funding. The most recent round was Series B. The last funding was announced in October 2025.
VitriVax's investors include RA Capital Management, Bill & Melinda Gates Foundation, Adjuvant Capital.
VitriVax is headquartered in Boulder, United States.
VitriVax is a formulation technology company that engineers solutions to maximize the accessibility and utility of human vaccines.
VitriVax is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"VitriVax — Funding & Investors." VCBacked, October 22, 2025, https://www.vcbacked.co/company/vitrivax. Accessed July 20, 2026.
VCBacked. (2025). VitriVax — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/vitrivax
{{cite web |title=VitriVax — Funding & Investors |url=https://www.vcbacked.co/company/vitrivax |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated